冠状动脉粥样硬化中肾素-血管紧张素系统的调节：文献综述
Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature.
作者信息
Hammoud Ramadan A, Vaccari Christopher S, Nagamia Sameer H, Khan Bobby V
机构信息
Emory University School of Medicine, Division of Cardiology, Grady Memorial Hospital Vascular Research Laboratory, Atlanta, Georgia 30303, USA.
出版信息
Vasc Health Risk Manag. 2007;3(6):937-45.
Activation of the renin-angiotensin system (RAS) is significant in the pathogenesis of cardiovascular disease and specifically coronary atherosclerosis. There is strong evidence that the RAS has effects on the mechanisms of action of atherosclerosis, including fibrinolytic balance, endothelial function, and plaque stability. Pharmacological inhibition of the renin angiotensin system includes angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and renin inhibitors. These agents have clinical benefits in reducing morbidity and mortality in the management of hypertension. In addition, ACE inhibitors and ARBs have shown to be effective in the management of congestive heart failure and acute myocardial infarction. This review article discusses the biochemical and molecular mechanisms involving the RAS in coronary atherosclerosis as well as the effects of RAS inhibition in clinical studies involving coronary atherosclerosis.
肾素-血管紧张素系统（RAS）的激活在心血管疾病尤其是冠状动脉粥样硬化的发病机制中具有重要意义。有充分证据表明，RAS对动脉粥样硬化的作用机制有影响，包括纤溶平衡、内皮功能和斑块稳定性。肾素血管紧张素系统的药理抑制包括血管紧张素转换酶（ACE）抑制剂、血管紧张素受体阻滞剂（ARB）和肾素抑制剂。这些药物在降低高血压管理中的发病率和死亡率方面具有临床益处。此外，ACE抑制剂和ARB已被证明在治疗充血性心力衰竭和急性心肌梗死方面有效。这篇综述文章讨论了RAS在冠状动脉粥样硬化中的生化和分子机制，以及RAS抑制在涉及冠状动脉粥样硬化的临床研究中的作用。
Zotero 插件